References

  1. NeuroStar Prescribing Information.
  2. Avery, et al. (2008). Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry, 69 (3):441-451.
  3. Janicak PG and Dokucu ME (2015). Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat, 11:1549–1560.
  4. Data on file. Neuronetics, Inc.
  5. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199. www.ncbi.nlm.nih.gov/pubmed/20965447
  6. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40
  7. Rush AJ, et. al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 163(11):1905-1917.
  8. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry. 75(12):1394-1401. www.ncbi.nlm.nih.gov/pubmed/25271871
  9. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216. www.ncbi.nlm.nih.gov/pubmed/17573044
  10. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516. www.ncbi.nlm.nih.gov/pubmed/20439832
  11. Kessler, RC et al. (2005). Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6):593-602.
  12. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  13. Gaynes BN, et al. (2008). Cleveland Clinic J of Medicine. 75(1):57-66.
  14. Post A, et al. (2001). J Psychiatric Research, 35:193-215 6.
  15. Liston C, et al.(2014). Biol Psychiatry, 76(7):517-26.
  16. https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018.
  17. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  18. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  19. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.